-+ 0.00%
-+ 0.00%
-+ 0.00%

Cryoport IntegriCell cryopreservation services win selection by Verismo Therapeutics for clinical KIR-CAR T trials

PUBT·06/25/2026 12:01:32
Listen to the news
Cryoport IntegriCell cryopreservation services win selection by Verismo Therapeutics for clinical KIR-CAR T trials
  • Cryoport announced Verismo Therapeutics selected its IntegriCell cryopreservation services to support two clinical KIR-CAR T cell therapy programs.
  • Scope includes process development, technology transfer, clinical cryopreservation services for SynKIR-110, SynKIR-310, both in Phase 1 trials.
  • Service delivery to run through IntegriCell centers in Houston, Texas, or Liège, Belgium, tied into Cryoport’s temperature-controlled supply chain platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryoport Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA91964) on June 25, 2026, and is solely responsible for the information contained therein.